You are viewing the site in preview mode
Skip to main content
|
Univariable
|
|
CpG sites
|
|
Per methylated site in Sseq
|
0.95 (< 0.01/0.93–0.97)
|
0.95 (< 0.01/0.94–0.97)
|
|
Age (years)
|
|
Per year
|
1.02 (< 0.01/1.00–1.03)
|
1.02 (< 0.01/1.01–1.04)
|
|
KPS
|
|
<80 versus ≥ 80
|
2.00 (< 0.01/1.36–2.94)
|
2.99 (< 0.01/2.01–4.45)
|
|
Tumor side
|
|
Left versus right
|
1.25 (n.s./0.95–1.64)
|
1.16 (n.s./0.87–1.53)
|
|
Tumor location
|
|
Lobar versus other
|
0.90 (n.s./0.68–1.20)
|
0.82 (n.s./0.61–1.1)
|
|
MSP status
|
|
Positive versus negative
|
0.44 (< 0.01/0.33–0.60)
|
0.45 (< 0.01/ 0.34–0.61)
|
|
Surgical treatment
|
|
OTR versus biopsy
|
0.64 (< 0.01/0.48–0.86)
|
0.59 (< 0.01/ 0.45–0.80)
|
|
Multivariable
|
|
CpG sites
|
|
Per methylated site in Sseq
|
0.96 (< 0.01/0.93–0.99)
|
0.95 (< 0.01/0.92–0.99)
|
|
Age (years)
|
|
P er year
|
1.02 (< 0.01/1.01–1.04)
|
1.03 (< 0.01/1.02–1.05)
|
|
KPS
|
|
< 80 versus ≥ 80
|
1. 94 (n.s./1.30–2.91)
|
2.88 (< 0.01/1.90–4.36)
|
|
Tumor location
|
|
Lobar versus other
|
1.04 (n.s./0.74–1.45)
|
1.08 (n.s./0.76–1.53)
|
|
MSP status
|
|
Positive versus negative
|
0.77 (n.s./0.44–1.34)
|
0.68 (n.s./0.37–1.26)
|
|
Surgical treatment
|
|
OTR versus biopsy
|
0.75 (n.s./0.54–1.03)
|
0.63 (< 0.01/0.44–0.89)
|
